{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'determined that such evaluation may provide additional information regarding subject safety', 'and efficacy of OKZ (e.g., due to unexpected immunogenicity results).', '7.3 Immunogenicity', 'Immunogenicity will be assessed by evaluating the impact of ADAs on subject safety and', 'efficacy of OKZ. Blood samples for analysis of the incidence and titer of antibodies to OKZ', 'and the incidence of any neutralizing antibodies to OKZ in plasma will be collected at the', 'times shown in Table 1.', 'The actual sample collection date and exact time will be entered on the Immunogenicity', 'Blood Collection eCRF page. Sampling problems will be noted in the Comments section of', 'the eCRF. All blood samples will be taken by either direct venipuncture or an indwelling', 'cannula inserted in a forearm vein. A Laboratory Manual will be provided to the Investigator', 'with detailed information on sample collection, handling, and shipment of the ADA samples.', 'Tubes and preprinted labels will be provided by the central laboratory to the study sites.', 'Antidrug antibody samples from all subjects who received OKZ will be analyzed, using', \"appropriately validated methods, by R-Pharm International or R-Pharm International's\", 'designee. Samples will initially be screened for antibodies. A confirmation assay will be', 'used to confirm the positive status for samples that scored potentially positive by the', 'Screening assay. In confirmed positive samples, the relative titer of the antibody will be', 'determined as well as whether the confirmed positive sample represents a neutralizing', 'antibody.', '7.4', 'Safety', 'Safety assessments will consist of monitoring and recording all AEs, including SAEs,', 'nonserious AESIs, and pregnancies; measurement of safety laboratory assessments;', 'measurement of vital signs, ECGs, physical examinations; and other tests that are deemed', 'critical to the safety evaluation of the study in all subjects who receive at least 1 dose of', 'study treatment. As discussed in Section 7.4.2.3, any pregnancy that occurs while a subject', 'is enrolled in the study will also be monitored and reported according to the appropriate', 'regulations.', 'The Investigator remains responsible for following, through an appropriate health care', 'option, AEs that are serious and nonserious that caused the subject to discontinue before', 'completing the study. Any AE, including any AE still ongoing at the end of the study,', 'should be followed until it has resolved, it has a stable sequelae, the Investigator determines', 'that it is no longer clinically significant, or the subject is lost to follow-up. If no follow-up is', 'provided, the Investigator must provide a justification.', 'Amendment 2: 06 March 2019', '96', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'In addition to records of observations made at specific times, unexpected signs and', 'symptoms and concomitant medications will be recorded in the clinical study records', 'throughout the study. The Investigator will also collect completed pages of the Subject Diary', '(see Section 5.5) at Visits 2 (Week 26) through 10 (EoT/Week 106), and the Investigator will', 'review any complaints, signs, or symptoms experienced by the subject in association with', 'administration of study treatment. Completed pages of the Subject Diary will serve as source', 'documents, and information will be recorded on the appropriate pages of the eCRF. The', 'Subject Diary will not be used during the Safety Follow-Up Period. Further routine medical', 'assessments in addition to those specified in Table 1 may take place during the study as', 'clinically indicated (e.g., chest X-rays to investigate lung lesions, ECG, etc).', 'Safety measures in this study include, but are not limited to, SAEs, AEs, vital signs, body', 'weight, and laboratory evaluations, and if required, this information must be present in the', 'AE/SAE report made by the Investigator.', '7.4.1', 'Adverse Events', 'For the purposes of this study, an AE will be defined as any untoward medical occurrence in', 'a subject or clinical investigation subject administered a pharmaceutical product and which', 'does not necessarily have a causal relationship with this treatment. An AE can therefore be', 'any of the following:', 'Any unfavorable and unintended sign, symptom, or disease temporally associated with', 'the use of a medicinal product, whether or not considered related to the medicinal', 'product.', '- If the Investigator determines a laboratory abnormality to be clinically significant, it', 'is considered a laboratory AE; however, if the abnormal laboratory value is consistent', 'with a current diagnosis (or signs or symptoms if a diagnosis is not possible) and is', 'not a clinically significant worsening from the baseline laboratory parameter, it', 'should be documented accordingly without being reported as a separate laboratory', 'AE.', 'Any new disease or exacerbation of an existing disease (a worsening in the character,', 'frequency, or severity of a known condition).', 'The Investigator is responsible for recording all AEs observed during the study starting at', 'Visit 1 (OLE Baseline/Week 24). All AEs are recorded throughout the study until the last', 'visit of the subject. The Investigator is responsible for the appropriate medical care of the', 'subjects during the entire study.', 'Amendment 2: 06 March 2019', '97', 'Confidential']\n\n###\n\n", "completion": "END"}